P1.07-022 Routine PD-L1 Immunohistochemistry Testing by 22C3 in a Canadian Reference Testing Center

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

BACKGROUND For non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Optimised protocols are urgently needed for use of the 22C3 antibody concentrate to test PD-L1 express...

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

[This corrects the article DOI: 10.1371/journal.pone.0183023.].

PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view

Tumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1). Checkpoint inhibitors (ICI) provide encouraging therapeutic results in non-small cell lung cancers (NSCLC) and may soon be used in 2nd or 1st line therapy. Currently PD-L1 immunohistochemistry (IHC) expression assessed on tumo...

HER2 Testing in Invasive Breast Cancer: a Comparison between Immunohistochemistry and FISH Assays

Making HIV Testing Routine

In 1996, approximately one quarter of the AIDS prevention budget of the CDC was allocated to HIV testing, predominantly for low-risk populations.1It was their single biggest HIV prevention expenditure. Dr Eric Goosby, then director of the HIV/AIDS Policy Office, argued that this “was not efficient nor effective in picking up HIV-positive people."1 Some dozen years later, the CDC is promulgating...